Palbo was approved 2 months early by the FDA--go oncology--the place to be. Analysts predicting $4B in sales per year in near future. At 10K per month we will have some interesting pricing conversations!
probably 500 mo in Canada and Europe. Exactly! Holding dying people hostage is a crime! For every one thing drug companies do they do 5 bad. Just wait until Medicare is allowed to negotiate prices. Goodbye Pharma.
Why do you think most of the new drug innovations come from the US you troll moron? because the profits attract talent and there is money to pump into R&D? How many drug innovations you see coming out of countries like the UK and France? Regulate pharma prices in the US and you kill the incentive and funding for innovation, no new drugs. Of course you would be one of the people bitching when pharma wasn't putting out any new drugs...
You've been drinking too much kool-aid. The R&D myth has been exposed for years. We spend three times as much on marketing vs. R&D. Charge the rest of the world the exorbitant prices to subsidize the US. They don't want to pay...screw em.. Pour healthcare system is ranked in the middle of the major countries in quality of care and # 1 in cost. Drugs are a major factor why. I'm the moron? Go back into your hole and shut up.
Totally agree. Rob your terminal, vulnerable patients so you can hand out big salaries to upper management who don't deserve them.
only idiots who obviously never faced cancer would say the stupid stuff said here. How lucky you must be to have no clue of what this means. You should use your evidently blessed life for something other than jerking off to anti-industry blogs. Pathetic, poor souls.
The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer. Breast cancer in women is the second most common type of cancer in the United States. It forms in the breast tissue and in advanced cases, spreads to surrounding normal tissue. The National Cancer Institute estimates that 232,670 American women were diagnosed with breast cancer and 40,000 died from the disease in 2014. Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole, another FDA-approved product used to treat certain kinds of breast cancer in postmenopausal women. “The addition of palbociclib to letrozole provides a novel treatment option to women diagnosed with metastatic breast cancer,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to expediting marketing approval of cancer drugs through our accelerated approval regulations.” The FDA granted Ibrance breakthrough therapy designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies. It also received a priority review, which provides for an expedited review of drugs intended to provide a significant improvement in safety or effectiveness in the treatment of a serious condition or meet an unmet medical need. Ibrance is being approved more than two months ahead of the prescription drug user fee goal date of April 13, 2015, the date when the agency was scheduled to complete its review of the application.
